🫀 Semaglutide shows neuroprotective potential: Lower neurodegenerative risk in T2D

🧪 What was studied — A massive, multinational, real-world cohort study (n=214,442; mean age 58.6; 2010-2021) compared people with T2D initiating GLP-1 RAs (including semaglutide) to DPP4i and basal insulin, tracking new-onset neurodegenerative diseases (Alzheimer’s, Parkinson’s, dementia types) for up to 5 years.

📈 Key results — GLP-1 RAs reduced neurodegeneration risk vs DPP4i (HR 0.81 [95% CI 0.77–0.86], absolute risk difference -0.6%). Benefits held for dementia (HR 0.76), Alzheimer’s (HR 0.77), and vascular dementia (HR 0.75); no signal for Parkinson’s. Subgroup data: robust risk reduction with semaglutide (HR 0.75), liraglutide (0.77), dulaglutide (0.82). Effects robust across age, sex, and comparisons with insulin.

📍 What this changes in practice — When selecting second-line agents for T2D, GLP-1 RAs—specifically semaglutide—may offer neuroprotective benefits compared to DPP4i or insulin. Counsel on potential extra-glycemic advantage in older adults and those at risk for dementia. Dedicated trials are needed to confirm causality.

🔗 Source — PubMed | Full text / DOI

🧪 Semaglutide gains FDA approval for MASH with advanced fibrosis: 2025 AASLD Guidance

🔥 Main in 3 points

• Wegovy® (semaglutide 2.4 mg/week) FDA-approved (Aug 2025, accelerated) for MASH (formerly “NASH”) with moderate–advanced fibrosis (F2–F3).
• Phase 3 (ESSENCE): MASH resolution in 62.9% vs 34.3% (placebo), ≥1 stage fibrosis reduction in 36.8% (vs 22.4%) after 72 weeks.
• Patient selection: Noninvasive testing (VCTE, MRE, ELF) preferred over biopsy; cirrhosis excluded.

🧪 Context — Updated AASLD guidance: Approved for biopsy-proven or NIT-defined MASH with stage 2–3 fibrosis; not for cirrhosis; careful monitoring for hepatic/renal/gallbladder/retinopathy AEs.

📍 Practical significance — Consider semaglutide (Wegovy®) in MASH-F2/3 patients. Don’t require biopsy—noninvasive risk stratification (e.g., VCTE/MRE/ELF) is generally sufficient. For cirrhosis, avoid unless used for a different indication, and monitor for complications.

🔗 Source — PubMed | Full text / DOI

⚠️ Semaglutide and diabetic retinopathy: No increased DR or DME risk in real-world data

🧪 Context — Large OHDSI network cohort study using 14 real-world databases; compared T2D patients (n=810,390 new semaglutide users) vs other GLP-1RAs and non-GLP-1RAs for incident proliferative diabetic retinopathy (PDR) and treatment-requiring DR/DME.

📊 Numbers — Semaglutide’s PDR risk was similar to dulaglutide, empagliflozin, and sitagliptin, and lower vs glipizide. DR/DME risk was even lower vs dulaglutide, sitagliptin, and glipizide; similar to empagliflozin. All HRs for PDR or DR/DME compared to other GLP-1RAs and non-GLP-1RAs were nonsignificant (except vs glipizide).

📍 Actions — No evidence for excess DR/DME risk with semaglutide versus major comparators in T2D. Maintain routine retinal monitoring, especially during glycemic transitions, but inform patients that current large real-world data do not indicate increased vision-threatening complications.

🔗 Source — PubMed | Full text / DOI

📘 2025 Cost-Effectiveness Analysis: Screening and semaglutide for MASH in T2D

✅ Do

• Screen T2D populations for MASH using ELF or VCTE—leads to cost-effective diagnosis/treatment.
• Offer intensive lifestyle interventions as the mainstay, add semaglutide where indicated (cost-effective in 11/12 countries).

⚠️ With caution

• For pharmacotherapy, tailor to local health system willingness-to-pay thresholds.

🚫 Avoid

• Delaying screening in T2D: substantial QALY and cost opportunity lost.

🔗 Source — PubMed | Full text / DOI

🫀 Semaglutide robustly reduces CV events in T2D: Enhanced benefit in CKD

🧪 What was studied — Systematic review/meta-analysis of 17 RCTs/observational studies (n=40,632; oral semaglutide vs placebo) with focus on T2D, CVD, and CKD subgroups.

📈 Key results — Semaglutide reduced CV death by 23% (HR 0.77), MACE by 18% (HR 0.82), nonfatal MI by 18% (HR 0.82), and stroke by 32% (HR 0.68). Effects strongest in T2D+CKD (24–37% risk reduction), plus SBP/DBP and LDL lowering. No impact on renal function (eGFR/UACR).

📍 What this changes in practice — Semaglutide should be prioritized for T2D patients with/at risk for CVD and CKD. Emphasize multi-risk reduction in patient discussions. CKD status appears to amplify benefit.

🔗 Source — PubMed | Full text / DOI